Mechanisms and application progress of metalloproteinase-7 in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis is a chronic fibrotic interstitial lung disease with a poor prognosis and unknown etiology.Early diagnosis,accurate disease assessment,and timely clinical intervention can improve patient's outcomes.Matrix metalloproteinase-7 is an active mediator secreted by alveolar epithelial cells after lung injury.It is notable for its role in predicting the prognosis of idiopathic pulmonary fibrosis and has research value in targeted therapy.The structural and nucleotide composition polymorphisms that distinguish matrix metalloproteinase-7 from other matrix metalloproteinase members,lead its broad functional range and efficient up-regulation.By understanding the clinical applications and action pathways of matrix metalloproteinase-7,the study exploring whether inhibiting its concentration could benefit idiopathic pulmonary fibrosis patients could provide new insights for early disease control.
idiopathic pulmonary fibrosismatrix metalloproteinase-7tissue inhibitors of metalloproteinasesmechanism of actionbiomarkers
国家科技期刊平台
NSTL
万方数据
